Attached files
EXHIBIT 99.1
CannaPharmaRx, Inc. Officially Opens
Headquarters in New Jersey
December 1, 2014: CannaPharmaRx, Inc., (OTC: GDHC), the New Jersey-based
pharmaceutical research and discovery company, officially took possession of its
new headquarters in Carney's Point Township in southwest New Jersey - a state
that is home to 14 of the 20 largest pharmaceutical companies in the world.
"Establishing our headquarters in New Jersey puts us in close proximity to some
of the most experienced pharmaceutical executives in the world." said Gerry
Crocker, CannaPharmaRx CEO. "Not only is it a rich source of human capital, it
is ideally geographically positioned for easy access to our staff and
development partners."
Pharmaceutical companies located in New Jersey include Johnson & Johnson,
Bristol-Myers Squibb, Merck & Co. and Novo Nordisk. Further, an estimated 22,000
students in New Jersey graduate each year with degrees in the life sciences from
New Jersey's colleges and universities.1 The state also boasts that its heavy
concentration of medical institutions and population density provides an
environment conducive to clinical trials.
The pharmaceutical industry in New Jersey benefits from its location, which is
within easy reach of major cities including New York, Philadelphia and
Baltimore. CannaPharmaRx's offices are in close proximity to Philadelphia
airport, Wilmington and Philadelphia train stations and the I-95 and New Jersey
Turnpike corridor.
CannaPharmaRx expects to derive value from various New Jersey tax incentives
provided to pharmaceutical companies who establish residence in the state.
About CannaPharmaRx: Headquartered in Carney's Point, New Jersey, CannaPharmaRx
is a pharmaceutical company whose mission is to advance cannabinoid discovery,
science, research & development, and to bring novel prescription, veterinary and
personal care cannabinoid-based products to market in the U.S. and worldwide.
For more information, visit www.cannapharmarx.com.
Forward Looking Statements: Certain statements in this press release are
forward-looking within the meaning of the Private Securities Litigation Reform
Act of 1995. These statements may be identified by the use of forward-looking
words such as "anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on CannaPharmaRx's
current expectations and actual results could differ materially. There are a
number of factors that could cause actual events to differ materially from those
indicated by such forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a going concern;
our need for additional financing; uncertainties of patent protection and
litigation; clinical trials involve a lengthy and expensive process with an
uncertain outcome, and results of earlier studies and trials may not be
predictive of future trial results; uncertainties of government or fourth party
payer reimbursement; limited sales and marketing efforts and dependence upon
fourth parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any pharmaceutical
products under development, there are significant risks in the development,
regulatory approval and commercialization of new products. There are no
guarantees that future clinical trials discussed in this press release will be
completed or successful or that any product will receive regulatory approval for
any indication or prove to be commercially successful. CannaPharmaRx does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in CannaPharmaRx's private
placement agreement and Form 10-Q as of September 30, 2014 (Unaudited) and other
periodic reports filed with the Securities and Exchange Commission.
SOURCE: CannaPharmaRx, Inc.
Contacts:
Ari Herrera, Interlinked, ari@interlinked.com
Delray Wannamaker, Interlinked, delray@interlinked.com
Kathleen Wolff, CannaPharmaRx, kwolff@cannapharmarx.co
